Whitehawk Therapeutics (WHWK) Operating Leases (2019 - 2024)
Historic Operating Leases for Whitehawk Therapeutics (WHWK) over the last 6 years, with Q4 2024 value amounting to $565000.0.
- Whitehawk Therapeutics' Operating Leases fell 5540.65% to $565000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $565000.0, marking a year-over-year decrease of 5540.65%. This contributed to the annual value of $565000.0 for FY2024, which is 5540.65% down from last year.
- Whitehawk Therapeutics' Operating Leases amounted to $565000.0 in Q4 2024, which was down 5540.65% from $946000.0 recorded in Q3 2024.
- Whitehawk Therapeutics' Operating Leases' 5-year high stood at $1.8 million during Q2 2022, with a 5-year trough of $9955.0 in Q2 2020.
- In the last 5 years, Whitehawk Therapeutics' Operating Leases had a median value of $1.1 million in 2024 and averaged $1.0 million.
- In the last 5 years, Whitehawk Therapeutics' Operating Leases plummeted by 9654.41% in 2020 and then surged by 26981.13% in 2023.
- Over the past 5 years, Whitehawk Therapeutics' Operating Leases (Quarter) stood at $9955.0 in 2020, then skyrocketed by 5977.35% to $605000.0 in 2021, then soared by 174.55% to $1.7 million in 2022, then decreased by 23.72% to $1.3 million in 2023, then crashed by 55.41% to $565000.0 in 2024.
- Its Operating Leases stands at $565000.0 for Q4 2024, versus $946000.0 for Q3 2024 and $1.1 million for Q2 2024.